Test your knowledge on progressive disease after treatment with both a BTK inhibitor and a BCL2 inhibitor
{"name":"Test your knowledge on progressive disease after treatment with both a BTK inhibitor and a BCL2 inhibitor", "url":"https://www.quiz-maker.com/QGUCXXVZS","txt":"Pirtobrutinib is currently FDA approved for use in which of the following diseases?, What was the approximate overall response rate of patients with relapsed\/refractory CLL\/SLL who had received prior BTKi and BCL2i (“double-refractory”) if partial response with lymphocytosis was included in the calculation?, Which of the following was the median progression-free survival for “double-refractory” patients with relapsed CLL\/SLL (i.e., those who had received prior BTKi and BCL2i therapy)?","img":"https://www.quiz-maker.com/3012/images/ogquiz.png"}
